Kidney and HF outcomes with SGLT2i across EF spectrum in HF - PACE-CME

Kidney and HF outcomes with SGLTi across EF spectrum in HF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

NOAC as possible treatment option in patients with AF after successful TAVI
NOAC as possible treatment option in patients with AF after successful TAVI
ESC 2021
NOAC as possible treatment option in patients with AF after successful TAVI
- Prof. Nicolas van Mieghem, MD, PhD
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
ESC 2021
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
- Prof Bertram Pitt
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
ESC 2021
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
- Prof. Frank Ruschitzka, MD
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
ESC 2021
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
- Prof. Stefan Anker, MD, PhD